Background. Randomized phase 3 trial reported 569 patients with relapsed refractory multiple myeloma

Arm A: Dara-RD*
Arm B: RD*

Primary end point: PFS
Median follow up: 44mo

mPFS: 44.5mo vs 17.5mo arm A vs arm B, HR 0.44, 95% CI 0.35-0.55, P<.0001

Main adverse events. Most common treatment emergent adverse event – neutropenia 63.3% arm A vs 48% arm B. Pulmonary embolism – 0% vs 1%. And second primary malignancy 8.5% vs 8.9% were similar

Conclusions. In patients with relapsed or refractory MM, treatment with Dara-RD resulted significantly improved PFS compared to RD

*
Daratumumab 16mg/kg IV QW x 8W , then Q2W x 16W, then Q4W until progression
Rd (lenalidomide 25mg PO D1-21 Q28D, dexamethasone 40mg QW)
 

Summarized by Thejus Jayakrishnan, MD

Send a feedback